Ignite Creation Date:
2024-05-06 @ 8:20 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06349772
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-05-07
First Post:
2024-04-01
Brief Title:
Zynrelef vs Exparel The Battle of Postoperative Pain Control After Robotic Sleeve Gastrectomy
Sponsor:
Texas Tech University Health Sciences Center
Organization:
Texas Tech University Health Sciences Center
Study Overview
Official Title:
Zynrelef vs Exparel The Battle of Postoperative Pain Control After Robotic Sleeve Gastrectomy
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the use of an injectable combination of bupivacaine and meloxicam Zynrelef vs injectable liposomal bupivacaine Exparel two extended local anesthesia strategies currently approved by FDA and on the market for post-surgical pain control The investigators plan on randomizing study participants to either Exparel or Zynrelef at the closure site of robotic sleeve gastrectomy and assessing their pain control postoperatively both in the hospital and at home The investigators will measure the outcome of two drugs Zynrelief and Exparel on postoperative pain score -using the NRS pin score up to 72 hours after surgery The total opioid use will be recorded in forms that will be used to measure pain score and total opioid use and will be collected to the Excel sheet The cost of the drug will be calculated for internal use for Hospital purpose only
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None